NDAORALCAPSULEPriority Review
Approved
Sep 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COGNEX (tacrine hydrochloride) is an oral capsule approved in 1993 for Alzheimer's disease, functioning as a cholinesterase inhibitor to increase acetylcholine levels in the brain. It was one of the first pharmacological treatments for cognitive decline in dementia patients. The drug works by reversibly inhibiting acetylcholinesterase, helping preserve remaining cholinergic function.
LOE Approaching
Product faces declining market share (30% competitive pressure) as newer agents dominate; small legacy team managing wind-down operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Roles linked to COGNEX reflect manufacturing and supply-chain optimization typical of legacy product stewardship, not commercial expansion. Career professionals joining this product focus on operational efficiency, regulatory compliance, and cost management rather than market growth.
Controls EngineerTÉCNICO ESPECIALIZADO EN AUTOMATIZACIÓN Y CONTROL
Worked on COGNEX at Shionogi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.